Epirubicin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Epirubicin and local guidelines before prescribing.
Anthracycline cytotoxic
Mechanism
Anthracycline.
Uses
Breast cancer, gastric cancer, lymphoma.
Dosing
- Anthracyclines (doxorubicin, epirubicin): Dose-dependent myocyte injury; risk rises steeply above a cumulative doxorubicin dose of about 250 mg/m², with mediastinal radiotherapy, older age, pre-existing heart disease and childhood exposure. Damage may present years later.
Cardiology: Cardiomyopathies
Side effects
Cardiomyopathy, myelosuppression, alopecia, mucositis, extravasation necrosis.
Interactions
Trastuzumab increases cardiotoxicity.
Contraindications and cautions
Cardiomyopathy
Monitoring
LVEF, FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in hepatic impairment
Overdose and reversal
Dexrazoxane for extravasation
Special advice
Cumulative dose record; echocardiogram.
More from the textbook: uses, cautions and other points
- Anthracyclines | Doxorubicin , epirubicin - cardiomyopathy (cumulative dose), red urine, severe tissue damage if they leak (extravasation), hair loss
Oncology: Principles - Heart failure years after breast cancer treatment with epirubicin | Anthracycline cardiomyopathy
Oncology: Principles
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Oncology: Principles (2 mentions)
- Integrated cardiology chapter (1 mention)